The Influence of Genetic Variants on Kidney Disease in African Populations

Evolutionary Perspective and Population Genetics

This raises the possibility that APOL1 variants are maintained by evolutionary pressure in African populations. These variants might have been positively selected because, as mentioned, these two forms of trypanosome were able to protect from African sleeping sickness. However, this selection also paved the way to increased vulnerability to chronic kidney disease, hence the significance of the study. For example, both types of APOL1 gene are present in African blacks but not in Europeans and therefore point to population risk factors of specific diseases.

Knowledge about the distribution of genes in the African population can also help to predict illnesses and factors provoking them. Population genetics show that Africans have some of the greatest human genetic variation, and from them, multiple lineages contributed to this variation. This significant genetic heterogeneity has many polymorphisms that are absent in other populations, including those affecting the prevalence of kidney disease. Also, African Americans are the descendants of people from different parts of the world, and the pattern of admixture complicated genetic risk assessment.

Clinical Implications of APOL1 Variants

It is argued that having risk variants in APOL1 brings up special problems in the clinical management of kidney disease. For instance, African Americans with these variants will not show a good response to usual therapy approaches to chronic kidney disease that reflect the results of clinical trials, including Europeans. Therefore, the development of further specific techniques for kidney disease treatment concerning the genetics of every person is required. Sometimes, a patient’s APOL1 status might help in the management of the case, like in cases of kidney transplantation, in which people, particularly those who have two copies of the APOL1 risk variants, exhibit higher rates of graft loss after transplant.

There are also moves to get genetic testing of APOL1 variants into clinical practice where it will be helpful in high-risk populations. Such testing could benefit both consumers and producers by giving further information, which could lead to a sooner diagnosis of chronic kidney disease and improved administration of it. Although there are some potential problems with this, there are also clear ethical and practical issues at stake, namely how to get truly informed consent and how to prevent genetic data from being used to reinforce prejudice against people who are already discriminated against.

The Role of Genetic Testing in Kidney Disease Management

Controversies persist about the use of genetic testing in kidney disease; nonetheless, it has implications for populations at a higher risk, such as the African ones. The clinical application of genetic test results is that people with positive test results can be more vigilant and receive early treatment for kidney disease. Moreover, knowledge of the patient’s predisposition can affect the selection of treatment strategies and dictate the conversation about what changes in diet, activity, and behavior might halt the progression of the disease.

There may also be important implications because genetic susceptibility testing must be coupled with culturally appropriate genetic counseling to enable patients to adequately comprehend their risks and make the appropriate health decisions. It is now clear that genetic risk means a probability of an illness outcome but shows a venue for possible action. Furthermore, for APOL1-associated kidney diseases, the prevalence of the APOL1 variants is very high and is particularly prevalent in African populations. Genetic testing may thus form part of the clinical and genetic screening approaches toward the control of kidney disease in these communities​ and other kidney diseases in such populations.

Public Health Implications

Understanding ways to address the severity rate that affects the African people and the kidney disease is not something that can be solved by only one approach. Biological findings stemming from genetic studies of this risk have proven ornamental in understanding the extent of the risk. and therefore there is a requirement for population health approaches that focus on social factors. For many African and African-American people with APOL1 variants, there are other health disparities, including poor access to health care, low income, and an increased burden of other diseases that predispose them to kidney disease.

In order to decrease existing disparities in health, there is a need to enhance the availability of insurance coverage for early detection, health promotion, and education services for at-risk groups. Moreover, the use of genetic risk factors in public health can lead to improved and personalized interventions accounting for the genetic and environmental causes of kidney diseases.

Conclusion

It can be stated that the identification of the APOL1 risk variants has greatly advanced the understanding of the elevated kidney disease prevalence in Africans and African Americans. New scientific data on the role of genetics in diseases’ development underline the need for implementing these discoveries into clinical and preventative policies effective for reducing the effects of kidney diseases in high-risk populations. Understanding these genetic as well as social factors affecting kidney disease will require concerted efforts among researchers, clinical practitioners, and policymakers. Thus, it is possible to approach the achievement of objectives that can contribute to the narrowing of disparities in health and enhance the quality of life of patients with chronic kidney diseases.

References

1. Popejoy, A.B., Ritter, D.I., Crooks, K., Currey, E., Fullerton, S.M., Hindorff, L.A., Koenig, B., Ramos, E.M., Sorokin, E.P., Wand, H. and Wright, M.W., 2018. The clinical imperative for inclusivity: race, ethnicity, and ancestry (REA) in genomics. Human mutation, 39(11), pp.1713-1720.
2. Martin, A.R., Gignoux, C.R., Walters, R.K., Wojcik, G.L., Neale, B.M., Gravel, S., Daly, M.J., Bustamante, C.D. and Kenny, E.E., 2017. Human demographic history impacts genetic risk prediction across diverse populations. The American Journal of Human Genetics, 100(4), pp.635-649.
3. Koehl, A.J. and Long, J.C., 2018. The contributions of admixture and genetic drift to diversity among post‐contact populations in the Americas. American journal of physical anthropology, 165(2), pp.256-268.
4. Bergström, A., McCarthy, S.A., Hui, R., Almarri, M.A., Ayub, Q., Danecek, P., Chen, Y., Felkel, S., Hallast, P., Kamm, J. and Blanché, H., 2020. Insights into human genetic variation and population history from 929 diverse genomes. Science, 367(6484), p.eaay5012.
5. Price, A.L., Tandon, A., Patterson, N., Barnes, K.C., Rafaels, N., Ruczinski, I., Beaty, T.H., Mathias, R., Reich, D. and Myers, S., 2009. Sensitive detection of chromosomal segments of distinct ancestry in admixed populations. PLoS genetics, 5(6), p.e1000519.
6. Mogil, L.S., Andaleon, A., Badalamenti, A., Dickinson, S.P., Guo, X., Rotter, J.I., Johnson, W.C., Im, H.K., Liu, Y. and Wheeler, H.E., 2018. Genetic architecture of gene expression traits across diverse populations. PLoS genetics, 14(8), p.e1007586.
7. Shi, J. and Lee, S., 2016. A novel random effect model for GWAS meta‐analysis and its application to trans‐ethnic meta‐analysis. Biometrics, 72(3), pp.945-954.
8. Tishkoff, S.A., Reed, F.A., Friedlaender, F.R., Ehret, C., Ranciaro, A., Froment, A., Hirbo, J.B., Awomoyi, A.A., Bodo, J.M., Doumbo, O. and Ibrahim, M., 2009. The genetic structure and history of Africans and African Americans. science, 324(5930), pp.1035-1044.